Neoadjuvant Umbrella Trial Directed by Next Generation Sequencing for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations (Without EGFR Sensitizing Mutations)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Dec 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Crizotinib (Primary) ; Dabrafenib (Primary) ; Ensartinib (Primary) ; Glecirasib (Primary) ; Larotrectinib (Primary) ; Pralsetinib (Primary) ; Pyrotinib (Primary) ; Savolitinib (Primary) ; Sunvozertinib (Primary) ; Trametinib (Primary)
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms NUMER

10 Dec 2024 Planned End Date changed from 1 Dec 2029 to 1 Nov 2029.
10 Dec 2024 Planned primary completion date changed from 1 Dec 2027 to 1 Nov 2027.
10 Dec 2024 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com